Glycobiology Market Forecasts Excellent Growth

Glycobiology products are widely used for analysis of cell surface markers, which can act as diagnostic or therapeutic targets. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.

According to the new market research report "Glycomics / Glycobiology Market by Product (Enzymes (Glycosyltransferase, Glycosidase), Instruments (HPLS, Mass Spectrometry, MALDITOF), Kits & Reagents (Glycoproteins)), Application (Diagnostic, Drug Discovery, Oncology), End User - Global Forecast to 2021", published by MarketsandMarkets™, The global glycobiology market is expected to reach USD 1,211.4 million by 2021 from USD 649.5 million in 2016, at a CAGR of 13.3%.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

Glycobiology Market Dynamics

Drivers

1. Increasing funding for Proteomics & glycomics research and growing

R&D expenditure

1. Growth of the proteomics market
2. Technological advancements in glycomics instrumentation

Restraints

1. High degree of consolidation acts as an entry barrier for new entrants
2. Stringent regulatory frameworks and time-consuming approval processes

Opportunities

1. Increased use of personalized medicine
2. Biomarkers identification
3. Developing countries and emerging markets

Challenges

1. High cost of tools and instruments and their maintenance

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525

Key Players and Strategies Adopted by Them:

The key players in the glycobiology market include Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).

Oncology :

Glycomics plays a crucial role in analyzing the molecular mechanism of various types of cancers. Glycomics also plays an important role in identifying new biomarkers for cancers. Biomarkers are used as key diagnostic targets for various types of cancers. They can also be used for devising novel and personalized therapies for cancer patients. Owing to its ability to differentiate between protein sub-types based on the molecular structure of their glycan patterns, glycomics has emerged as an important research tool for the discovery and validation of protein-based cancer biomarkers.

Increasing funding for proteomics & glycomics research and growing R&D expenditure drives the global glycomics market :

The growing demand for remedial treatments for life-threatening diseases, such as cancer, has driven the pace of pharmaceutical and biotechnological R&D as well as overall investments made in this sector. Both glycomics (being the study of glycans) and proteomics (being the study of proteins, and holding a prominent place in glycome R&D) are research-driven sectors. Moreover, glycomic Biomarkers are finding significant applications in drug development and diagnostics for such diseases. As a result, the growing availability of funding for these two sectors is expected to aid the growth of the glycobiology market, in the coming years.

Glycomics is a promising approach to biomarker discovery and validation. The development of various separation techniques coupled with the advanced structure determination capabilities of this field makes possible the separation and identification of thousands of glycans from complex mixtures. Biomarker identification presents significant opportunities for the glycomics market. Glycomics also has a wide range of applications in drug development and enhancement. Glycomics products such as enzymes, kits, and reagents are often used in investigating the role of sugars in the development and progression of diseases like cancer, Alzheimer’s, Parkinson’s, and various infectious diseases like herpes and AIDS.

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.